Pharmacoeconomic evaluation of glucose-lowering therapy with insulin alone or in combination with a dipeptidyl peptidase-4 inhibitor (DPP-4) vildagliptin in patients with type 2 diabetes.
Material and methods
Previously, it was shown that the combination of a DPP-4 inhibitor and insulin can reduce the insulin dose by 18%. Two treatment options were compared in terms of cost-effectiveness (CER - Cost Effectiveness Ratio) at reducing HbA1c levels by 1%. Costs for relief of severe hypoglycemia included the ambulance call and required manipulations.
The addition of vildagliptin to insulin therapy reduces the cost of drug therapy by up to 10.3% in patients who are overweight and receiving high doses of insulin. CER of combination therapy with insulin and vildagliptin was 1.52.8-fold lower compared with that of insulin alone. Upon reaching the same efficacy addition of vildagliptin to insulin reduces the necessary costs by 34.1-64.3%.
The addition of vildagliptin to insulin therapy pharmacoeconomically is more effective medical technology compared with insulin monotherapy.
Type 2 diabetes, dipeptildyl peptidase-4 inhibitor, vildagliptin, insulin, pharmacoeconomic analysis.